Breast cancer and thrombosis: Timing matter

Blood

Volumn 127, Issue 7, 2016, Pages 793-794

  Paulus, Essica K ^a   Rosenberg, Aaron S ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AROMATASE INHIBITOR; TAMOXIFEN;

ANTICOAGULATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISTANT METASTASIS; FOLLOW UP; HUMAN; NOTE; OBESITY; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TIME TO TREATMENT; VENOUS THROMBOEMBOLISM; BREAST NEOPLASMS; FEMALE; REGISTER;

BREAST NEOPLASMS; FEMALE; HUMANS; REGISTRIES; VENOUS THROMBOEMBOLISM;

EID: 84959421784     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-12-683482     Document Type: Note

References (9)

1. Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016;127(7):849-857.
2. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25(1): 70-76.
3. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
4. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost. 2012;108(6): 1042-1048.
5. Lyman GH, Bohlke K, Khorana AA, et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6): 654-656.
6. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56-70.
7. Kent DM, Lindenauer PK. Aggregating and disaggregating patients in clinical trials and their subgroup analyses. Ann Intern Med. 2010;153(1): 51-52.
8. Agnelli G, George DJ, Kakkar AK, et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609.
9. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial. J Clin Oncol. 2015;33(18): 2028-2034.